← Human Trials & Peer-Reviewed Studies
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
Plain-language guide to PMID 33035599 (2020): placebo-controlled randomized controlled trial study of Insulin Glargine and Liraglutide in 2018, patients, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 33035599
- Journal
- Diabetes research and clinical practice
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Guo W et al. (4 authors)
- DOI
- 10.1016/j.diabres.2020.108487
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Glargine and Liraglutide in the context of fatty liver & elevated liver enzymes.
Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD).
Who Took Part
The study group was 2018, patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
From September 2016 to July 2018, 128 patients with type 2 diabetes and NAFLD were enrolled in the China joint logistics team 900 hospital.
The primary endpoints were the changes in intrahepatic content of lipid (IHCL), abdominal adiposity [subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)], from baseline to week 26 (end of treatment) and the changes in liraglutide group or insulin glargine group versus change in placebo group.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The patients were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Insulin Glargine group a baseline to be compared against.
This is a 26-week, single-center, prospective, randomized placebo-controlled study.
Secondary endpoints included the changes in liver function (AST and ALT), glycemia (HbA1c and FPG), body weight, and BMI.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, China, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Glargine and Intra-Abdominal Fat.
Author keywords: Intrahepatic content of lipid, Liraglutide, Nonalcoholic fatty liver disease and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Insulin Glargine and Liraglutide in 2018, patients in people with fatty liver & elevated liver enzymes.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2020 (Diabetes research and clinical practice), a journal based in Ireland.
More context: the Insulin Glargine compound page and the Liraglutide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
- Fatty liver & elevated liver enzymes research
- Insulin Glargine in the library
- Liraglutide in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.